Status:
COMPLETED
Study of AT-752 in Healthy Subjects
Lead Sponsor:
Atea Pharmaceuticals, Inc.
Conditions:
Dengue
Eligibility:
All Genders
18-65 years
Phase:
PHASE1
Brief Summary
This study will assess the safety, tolerability and pharmacokinetics (PK) of AT-752 in healthy subjects
Detailed Description
A First-in Human, Randomized, Double-blind, Placebo controlled Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of AT-752 in Healthy Subjects
Eligibility Criteria
Inclusion
- Body mass index (BMI) of 18-29 kg/m2
- Must agree to use protocol-specified methods of contraception
- Negative pregnancy test
- Willing to comply with the study requirements and to provide written informed consent
Exclusion
- Pregnant or breastfeeding
- Abuse of alcohol or drugs
- Use of other investigational drugs within 30 days of dosing
- Other clinically significant medical conditions
Key Trial Info
Start Date :
March 9 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 14 2021
Estimated Enrollment :
65 Patients enrolled
Trial Details
Trial ID
NCT04722627
Start Date
March 9 2021
End Date
November 14 2021
Last Update
October 17 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Atea Study Site
Melbourne, Victoria, Australia, 3004